US Pharma MarketingBrand-name drug prices climb after launch in US, fall abroad amid MFN push: report
List prices for 25 top brand-name drugs rose an average of 81% after launch in the U.S., while prices for the same medicines fell an average of 13% abroad, according to a new AARP analysis. The findings land as Medicare negotiation starts to pressure some list prices and the White House pushes "most favored nation" pricing.
List prices for 25 top brand-name drugs rose an average of 81% after launch in the U.S., while prices for the same medicines fell an average of 13% abroad, according to a new AARP analysis. The findings land as Medicare negotiation starts to pressure some list prices and the White House pushes "most favored nation" pricing.
Source: FiercePharma